Royal Brompton & Harefield NHS Foundation Trust

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Private

Employees: -

Market Cap: -

Website: http://www.rbht.nhs.uk

Clinical Trials

Oral Allergy Syndrome (OAS): a Pilot Study to Evaluate a Clinical Questionnaire as a Diagnostic Tool

Completed

Conditions: Rhinitis
Food Allergy

First Posted Date: 2007-01-29

Last Posted Date: 2007-01-29

Lead Sponsor: Royal Brompton & Harefield NHS Foundation Trust

Target Recruit Count: 40

Registration Number: NCT00427479

Locations: 🇬🇧
Royal Brompton & Harefield NHS TRust, London, United Kingdom

CMR to Assess Fibrosis in Cardiomyopathy Using Eplerenone

Phase 4

Completed

Conditions: Cardiomyopathy

Interventions: Drug: Eplerenone
Drug: Placebo

First Posted Date: 2006-11-22

Last Posted Date: 2021-09-21

Lead Sponsor: Royal Brompton & Harefield NHS Foundation Trust

Target Recruit Count: 42

Registration Number: NCT00401856

Locations: 🇬🇧
Royal Brompton & Harefield NHS Trust, London, United Kingdom

Sequestration of Platelets Prior to Bypass Reduces Bleeding After Cardiac Surgery

Phase 2

Terminated

Conditions: Cardiac Surgical Procedures
Cardiopulmonary Bypass
Blood Coagulation Disorders
Blood Platelet Disorders

Interventions: Procedure: Platelet rich plasma sequestration

First Posted Date: 2006-08-02

Last Posted Date: 2016-04-14

Lead Sponsor: Royal Brompton & Harefield NHS Foundation Trust

Target Recruit Count: 30

Registration Number: NCT00359398

Locations: 🇬🇧
Royal Brompton Hospital, London, United Kingdom

The Use of Inflammatory Markers to Guide Therapy in Children With Severe Asthma

Not Applicable

Completed

Conditions: Asthma

Interventions: Other: Non invasive measurement of airway inflammation

First Posted Date: 2005-12-06

Last Posted Date: 2015-10-29

Lead Sponsor: Royal Brompton & Harefield NHS Foundation Trust

Target Recruit Count: 55

Registration Number: NCT00262340

Locations: 🇬🇧
Royal Brompton Hospital, London, United Kingdom

Cystic Fibrosis Withdrawal of Inhaled Steroids Evaluation Study (CF WISE Study)

Not Applicable

Completed

Conditions: Cystic Fibrosis

First Posted Date: 2005-09-22

Last Posted Date: 2005-11-08

Lead Sponsor: Royal Brompton & Harefield NHS Foundation Trust

Target Recruit Count: 240

Registration Number: NCT00220259

Locations: 🇬🇧
Royal Brompton Hospital, London, United Kingdom

Assessment of Heart and Heart-Lung Transplant Patient Outcomes Following Pulmonary Rehabilitation

Phase 1

Conditions: Emphysema
Alveolitis, Fibrosing
Cystic Fibrosis
Bronchiectasis
Lung Diseases

First Posted Date: 2005-08-11

Last Posted Date: 2005-09-07

Lead Sponsor: Royal Brompton & Harefield NHS Foundation Trust

Target Recruit Count: 60

Registration Number: NCT00129350

Locations: 🇬🇧
Harefield Hospital, Harefield, United Kingdom

The Early High Risk Period for Patients With Heart Failure

Conditions: Heart Failure, Congestive

First Posted Date: 2005-08-05

Last Posted Date: 2006-02-13

Lead Sponsor: Royal Brompton & Harefield NHS Foundation Trust

Target Recruit Count: 450

Registration Number: NCT00127322

Locations: 🇬🇧
The Conquest Hospital, Hastings, United Kingdom
🇬🇧
Hillingdon Hospital, Pield Heath Road, London, United Kingdom

Programme to Optimise Risk Factors in Patients Waiting for Coronary Artery Bypass Surgery

Phase 2

Completed

Conditions: Coronary Artery Disease

First Posted Date: 2005-07-27

Last Posted Date: 2005-08-05

Lead Sponsor: Royal Brompton & Harefield NHS Foundation Trust

Target Recruit Count: 200

Registration Number: NCT00124371

Locations: 🇬🇧
Royal Brompton and Harefield NHS Trust, London, United Kingdom

Rosiglitazone Plaque Study

Phase 3

Conditions: Diabetes Mellitus, Type 2
Vascular Diseases
Hypertension

First Posted Date: 2005-07-22

Last Posted Date: 2005-08-01

Lead Sponsor: Royal Brompton & Harefield NHS Foundation Trust

Target Recruit Count: 60

Registration Number: NCT00123227

Locations: 🇬🇧
St Mary's NHS Trust, London, United Kingdom
🇬🇧
Cardiovascular Magnetic Resonance Unit, Royal Brompton Hospital, London, United Kingdom

Combined Chelation Treatment With Deferiprone and Deferoxamine in Thalassemia Major

Phase 4

Conditions: Beta-Thalassemia

First Posted Date: 2005-02-15

Last Posted Date: 2005-06-24

Lead Sponsor: Royal Brompton & Harefield NHS Foundation Trust

Target Recruit Count: 65

Registration Number: NCT00103753

Locations: 🇮🇹
Ospedale Microcitemico, Via Jenner, Cagliari, Sardinia, Italy

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy